• Molecular NameAzacitidine
  • Synonym5 AZC; Azacitidina [INN-Spanish]; azacitidine; Azacitidinum [INN-Latin]; Azacytidine
  • Weight244.207
  • Drugbank_IDDB00928
  • ACS_NO320-67-2
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)-2.75
  • pkaN/A
  • LogD (pH=7, predicted)-2.75
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.26
  • LogSw (predicted, AB/LogsW2.0)41.7
  • Sw (mg/ml) (predicted, ACD/Labs)13.51
  • No.of HBond Donors5
  • No.of HBond Acceptors9
  • No.of Rotatable Bonds2
  • TPSA140.97
  • StatusFDA approved
  • Administrationsubcutaneous, intravenous
  • PharmacologyA chemical analogue of cytidine, a nucleoside present in DNA and RNA. Azacitidine and its deoxy derivative, decitabine (also known as 5-aza-2′deoxycytidine), are used in the treatment of myelodysplastic syndrome.
  • Absorption_valueN/A
  • Absorption (description)Azacitidine is rapidly absorbed after subcutaneous administration. The bioavailability of subcutaneous azacitidine relative to IV azacitidine is approximately 89%, based on area under the curve.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A